NK cells mediate clearance of CD8⁺ T cell-resistant tumors in response to STING agonists.

ABSTRACT: Several immunotherapy approaches that mobilize CD8⁺ T cell responses stimulate tumor rejection, and some, such as checkpoint blockade, have been approved for several cancer indications and show impressive increases in patient survival. However, tumors may evade CD8⁺ T cell recognition via loss of MHC molecules or because they contain few or no neoantigens. Therefore, approaches are needed to combat CD8⁺ T cell-resistant cancers. STING-activating cyclic dinucleotides (CDNs) are a new class of immune-stimulating agents that elicit impressive CD8⁺ T cell-mediated tumor rejection in preclinical tumor models and are now being tested in clinical trials. Here, we demonstrate powerful CDN-induced, natural killer (NK) cell-mediated tumor rejection in nume

SUBMITTER: Nicolai CJ 

PROVIDER: S-EPMC7228660 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature